1. Home
  2. ENVB
  3. Earnings

AI Earnings Predictions for Enveric Biosciences Inc. (ENVB)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-4.02%

$1.46

0% positive prob.

5-Day Prediction

-9.55%

$1.37

0% positive prob.

20-Day Prediction

-13.37%

$1.32

0% positive prob.

Price at prediction: $1.52 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -4.02% -9.55% -13.37% 100.0% Pending
Q2 2026 SELL -4.00% -9.77% -8.57% 100.0% Pending
Q1 2026 BUY +1.43% +7.43% +40.01% 100.0% -1.11%
Q3 2025 SELL -4.03% -10.86% -5.41% 100.0% +9.47%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 13, 2026 · 100% conf.

AI Prediction SELL

1D

-4.02%

$1.46

Act: -4.28%

5D

-9.55%

$1.37

20D

-13.37%

$1.32

Price: $1.52 Prob +5D: 0% AUC: 1.000
0001493152-26-051708

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update

EB-003

Development Highlights:

●Advancing final IND-enabling activities to support the planned EB-003 IND application

●Completed IND-enabling absorption and metabolic studies with favorable findings supporting EB-003’s potential for reduced drug-drug interactions

●Reported preclinical qEEG results demonstrating brain penetration and activity distinct from DMT, supporting evaluation as a potential biomarker

●Reported in vitro mechanistic studies, supporting EB-003’s predicted non-hallucinogenic profile

Corporate and Business Development Highlights:

●Secured U.S. patent allowance for next-generation, non-hallucinogenic mescaline derivatives in EVM401 Series

●Supported the FDA release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics.

CAMBRIDGE,

Mass., November 13, 2026 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a comprehensive business update.

CEO Commentary:

“Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned IND submission and first-in-human Phase 1 clinical trial of our lead non-hallucinogenic, neuroplastogenic candidate,” said Joseph Tucker, Ph.D., Chief Executive Officer of Enveric. “The data generated during the quarter and in recent weeks strengthen the foundation for this next stage and reinforce the opportunity to develop EB-003 as a differentiated treatment for psychiatric and neurological disorders.”

Dr. Tucker continued: “Recently completed studies of EB-003 have provided important, complementary evidence demonstrating its differentiated profile and potential advantages. Independent assay platforms, including GloSensor™ and BRET, have consistently supported its predicted non-hallucinogenic profile, while our completed in vitro ADMET studies indicate favorable absorption and metabolic properties and a reduced potential for drug-drug interactions. The qEEG study adds functional evidence of brain penetration and a pattern of brain activity distinct from dimethyltryptamine (DMT). It also supports evaluating qEEG in human studies to connect drug exposure with brain activity and help guide dose selection.”

“As the FDA continues to define the regulatory framework for psychedelic-inspired therapies, we believe EB-003’s design has the potential to offer advantages in clinical development while supporting broader patient access and potential commercial adoption,” Dr. Tucker concluded. “By seeking to harness the therapeutic potential of neuroplasticity without requiring a hallucinogenic experience, our approach could support a simpler outpatient treatment model. The growing body of preclinical evidence reinforces our confidence in this opportunity as we complete the final IND-enabling activities and prepare to advance EB-003 toward first-in-human clinical development.”

THIRD

QUARTER 2026 AND RECENT BUSINESS HIGHLIGHTS

Corporate, Product and Business Development Highlights:

EB-003

Development:

●Reported a preclinical qEEG study demonstrating functional evidence of central nervous system penetration and a brain activity profile distinct from the classic psychedelic DMT

○Results support use of qEEG as a potential pharmacodynamic biomarker in first-in-human development

●Announced positive results from recently completed IND-enabling in vitro Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) studies for EB-003

●Reported findings from a highly sensitive GloSensor™ cAMP assay that provided additional evidence supporting EB-003’s predicted non-hallucinogenic profile

●Supported the release of finalized guidance from FDA for clinical investigations of psychedelic and psychedelic-inspired therapeutics

Intellectual Property:

●Secured New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

THIRD

QUARTER FINANCIAL RESULTS

Net loss attributable to stockholders was $2.5 million for the third quarter ended September 30, 2026, including $0.2 million in net non-cash expense, with a basic and diluted loss per share of $0.57, as compared to a net loss attributable to stockholders of $3.4 million, including $0.1 million in net non-cash expense, with a basic and diluted loss per share of $10.81 for the quarter ended September 30, 2025. The net loss attributable to stockholders for the quarter ended September 30, 2025 also included a $1.5 million deemed dividend on the inducement of warrants, which did not recur in the quarter ended September 30, 2026. The Company had cash-on-hand of $5.6 million as of September 30, 2026.

About

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 14, 2026 · 100% conf.

AI Prediction SELL

1D

-4.00%

$1.47

Act: -3.58%

5D

-9.77%

$1.39

20D

-8.57%

$1.40

Price: $1.53 Prob +5D: 0% AUC: 1.000
0001493152-26-038385

Transcript text not available. View on SEC.gov →

2026
Q1

Q1 2026 Earnings

8-K BUY

May 15, 2026 · 100% conf.

AI Prediction BUY

1D

+1.43%

$2.27

Act: -3.80%

5D

+7.43%

$2.40

Act: -1.11%

20D

+40.01%

$3.13

Price: $2.23 Prob +5D: 100% AUC: 1.000
0001493152-26-023345

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026

Product Development Highlights:

●Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial

●Reported additional preclinical data for EB-003 demonstrating dual Gq and β-arrestin signaling at 5-HT2A, pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects

Corporate and Business Development Highlights:

●Strengthened intellectual property portfolio with new patent issuances and allowances across EVM301 and EVM401 series

●Announced the withdrawal by AbbVie, Inc. of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276, which appears relevant to the bretisilocin molecule (GM-2505) acquired by AbbVie, Inc.

●Presented at and Participated in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

CAMBRIDGE,

Mass., May 15, 2026 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a comprehensive business update.

CEO Commentary:

“Our progress in the first quarter of 2026 reflects continued execution against our core mission of developing therapeutics capable of addressing the significant unmet need in mental health,” said Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences. “We remain laser focused on advancing EB-003, Enveric’s lead drug candidate in developlment, toward an IND submission and first-in-human clinical trials.”

Dr. Tucker continued: “What differentiates Enveric is our commitment to harnessing the therapeutic potential of psychedelic-inspired mechanisms while designing our candidates to eliminate the hallucinogenic effects that limit scalability, safety, and broad patient access. Our growing body of preclinical data continue to support EB-003’s ability to promote neuroplasticity through selective receptor engagement, reinforcing our confidence in its potential to deliver rapid and durable antidepressant and anxiolytic effects.”

“Since the end of the first quarter, the broader policy environment appears to be increasingly supportive of innovation in mental health. Recent actions, including an Executive Order issued under President Donald Trump emphasizing the importance of advancing novel treatments for mental health conditions, underscore growing recognition of the therapeutic promise of psychedelic-inspired compounds. We believe the future of this field will be defined by non-hallucinogenic neuroplastogens like EB-003, which is designed to deliver the benefits of these pathways while avoiding the limitations associated with traditional psychedelic therapies.”

Dr. Tucker continued: “In parallel, we continue to view our intellectual property estate as a foundational driver of long-term value creation. The recent withdrawal of the Post-Grant Review petition by AbbVie further underscores the strength, breadth and strategic relevance of our patent portfolio. We believe our expanding IP position not only protects our innovations but also enhances our ability to create future partnering and monetization opportunities.”

Dr. Tucker concluded: “With IND-enabling activities underway and a strong intellectual property position, we believe Enveric is well positioned to generate meaningful value for stockholders as we transition toward the clinical phase of drug development.”

FIRST

QUARTER 2026 AND RECENT BUSINESS HIGHLIGHTS

Corporate, Product and Business Development Highlights:

EB-003

Development:

●Reported EB-003 BRET receptor engagement assay data, demonstrating dual Gq and β-arrestin signaling at 5-HT2A, pathways that have been linked in peer-reviewed studies to antidepressant and anxiolytic effects

●Subsequent to the end of the first quarter, highlighted positive results for EB-003 indicating a rapid reduction in conditioned fear response in a validated preclinical model of PTSD, supporting continued development for patient population with significant unmet need

Intellectual Property:

●Announced the withdrawal of the Post-Grant Review (PGR) petition, which had been filed by Gilgamesh Pharmaceuticals, pertaining to patents that appear relevant to the bretisilocin (GM-2505) molecule, which was acquired by AbbVie, Inc. in $1.2 billion deal

●Added depth to EVM301 intellectual property portfolio for non-hallucinogenic treatment of neuropsychiatric conditions, enhancing the patent claim coverage of Enveric’s N-heterocycle substituted tryptamine derivative molecules

●Registered five of the Company’s trademarks, including its house marks, Enveric and Enveric Biosciences, with the Canadian

About Enveric Biosciences Inc. (ENVB) Earnings

This page provides Enveric Biosciences Inc. (ENVB) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ENVB's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: